



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

WITHDRAWN: Remdesivir investigational trials in coronavirus disease 2019: a critical reappraisal[☆]

P. Brouqui^{1,2,*}, A. Giraud-Gatineau^{1,2}, D. Raoult^{1,2}

¹⁾ Aix Marseille Université, IRD, MEPHI

²⁾ AP-HM, IHU-Méditerranée Infection

Received 7 May 2020; revised 2 June 2020; accepted 4 June 2020 **Article published online:** 7 June 2020

The Publisher regrets that this article is an accidental duplication of an article that has already been published, <https://doi.org/10.1016/j.nmni.2020.100745>. The duplicate article has therefore been withdrawn.

The full Elsevier Policy on Article Withdrawal can be found at <https://www.elsevier.com/about/our-business/policies/article-withdrawal>.

[☆] This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

^{*} Corresponding author: P. Brouqui, AP-HM, IHU-Méditerranée Infection, Marseille, France.
E-mail address: philippe.brouqui@univ-amu.fr (P. Brouqui).